Skip to search formSkip to main contentSkip to account menu

PF 04971729

Known as: PF-04971729, PF04971729 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Applicant : Mapi Pharma Ltd . , Ness Ziona ( IL ) s : R : 3 .
  • Spal
  • 2017
  • Corpus ID: 55897082
US 2014/O34301.0 A1 Nov. 20, 2014 pageS. BMS-AstraZeneca Dapagliflozin Diabetes Drug Falls Short; Pfizer's Related U.S… 
2013
2013
Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes
  • 2013
  • Corpus ID: 62782968
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada (“Merck”), and Pfizer Inc. (NYSE:PFE) today… 
2012
2012
Metabolism and Excretion of the Anti-Diabetic Agent Ertugliflozin ( PF-04971729 ) in Healthy Male Subjects
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)